The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2 f/r).
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Mitesh Borad
Consulting or Advisory Role - Genentech; Guardant Health; Kriya Therapeutics; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Compass Therapeutics (Inst); Elevar Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Merck Serono (Inst); Nuvectis Pharma (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst); ZielBio (Inst)
 
Peter Lu
Employment - Elevar Therapeutics
 
Xianzhang Meng
Employment - Elevar Therapeutics
 
Kristin Ryan
Employment - Elevar Therapeutics
 
Laura Alexander
Employment - Elevar Therapeutics
 
Jia Liu
Honoraria - Specialised Therapeutics
Consulting or Advisory Role - Greywolf Therapeutics (Inst); Starpharma (Inst); Taiho Pharmaceutical
Research Funding - Abbvie (Inst); ALX Oncology (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bristol Ms Squibb (Inst); Bristol-Myers Squibb (Inst); Carina Biotech (Inst); Greywolf Therapeutics (Inst); IDEAYA Biosciences (Inst); ImmVirX (Inst); Innovent Biologics (Inst); Merus (Inst); MSD (Inst); Nested Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Starpharma (Inst)
Travel, Accommodations, Expenses - ImmVirX; Innovent Biologics; MSD; Starpharma
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Hanmi; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Revolution Medicines; Taiho Pharmaceutical; Tallac Therapeutics; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Hanmi; Lilly; MSD; Novartis; SERVIER
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte